Baseline demographics for the overall group and the inoperable and persistent/recurrent PH following PEA subgroups
| Inoperable CTEPH | Persistent/recurrent PH following PEA | All patients | ||||
|---|---|---|---|---|---|---|
| Characteristic | Riociguat (n=121) | Placebo (n=68) | Riociguat (n=52) | Placebo (n=20) | Riociguat (n=173) | Placebo (n=88) |
| Female sex, n (%) | 86 (71) | 45 (66) | 32 (62) | 9 (45) | 118 (68) | 54 (61) |
| Race, n (%) | ||||||
| White | 76 (63) | 49 (72) | 44 (85) | 16 (80) | 120 (69) | 65 (74) |
| Black | 5 (4) | 0 | 2 (4) | 1 (5) | 7 (4) | 1 (1) |
| Asian | 32 (26) | 17 (25) | 5 (10) | 3 (15) | 37 (21) | 20 (23) |
| Multiple | 1 (1) | 0 | 0 | 0 | 1 (1) | 0 |
| Not reported | 7 (6) | 2 (3) | 1 (2) | 0 | 8 (5) | 2 (2) |
| Mean age (SD), years | 59 (14) | 60 (12) | 60 (14) | 57 (15) | 59 (14) | 59 (13) |
| Mean BMI (SD), kg/m2 | 27 (5) | 28 (5) | 28 (7) | 28 (6) | 27 (6) | 28 (5) |
| WHO FC, n (%)* | ||||||
| I | 2 (2) | 0 | 1 (2) | 0 | 3 (2) | 0 |
| II | 38 (31) | 18 (26) | 17 (33) | 7 (35) | 55 (32) | 25 (28) |
| III | 75 (62) | 49 (72) | 32 (62) | 11 (55) | 107 (62) | 60 (68) |
| IV | 6 (5) | 1 (1) | 2 (4) | 1 (5) | 8 (5) | 2 (2) |
| Missing | 0 | 0 | 0 | 1 (5) | 0 | 1 (1) |
| Mean 6MWD (SD), m | 335 (83) | 351 (75) | 360 (78) | 374 (72) | 342 (82) | 356 (75) |
*Data may not add up to 100% due to rounding.
6MWD, 6 min walk distance; BMI, body mass index; CTEPH, chronic thromboembolic pulmonary hypertension; PEA, pulmonary endarterectomy; PH, pulmonary hypertension; WHO FC, WHO functional class.